Eli Lilly Taps Blue-Chip Bond Market to Fund Morphic Acquisition – Bloomberg

Eli Lilly is using the blue-chip bond market to finance its acquisition of Morphic. The pharmaceutical company is turning to this market to secure the funding needed for the deal. This move allows Eli Lilly to access the capital necessary to complete the acquisition. The decision to tap into the blue-chip bond market underscores the company’s commitment to expanding its portfolio and investing in new ventures. By utilizing this market, Eli Lilly is able to efficiently raise funds for the acquisition of Morphic. The pharmaceutical giant’s strategic approach to financing the deal highlights its dedication to growth and innovation in the industry.